放疗联合替吉奥与单纯放疗治疗老年食管癌患者的效果比较
|
摘要
目的比较放疗联合替吉奥与单纯放疗治疗老年食管癌患者的疗效。方法将60例老年食管癌患者按随机数字表法分为单纯放疗组及联合组,每组30例。单纯放疗组采用单纯放疗治疗,联合组采用放疗联合替吉奥治疗,比较两组患者治疗后的疗效、不良反应发生情况及1年生存率。结果联合组患者总有效率为86.67%(26/30),高于单纯放疗组的60.00%(18/30),差异有统计学意义(P﹤0.05)。联合组患者骨髓抑制、恶心呕吐发生率均高于单纯放疗组,差异均有统计学意义(P﹤0.05);两组患者腹泻、放射性食管炎、放射性肺炎发生率比较,差异均无统计学意义(P﹥0.05)。联合组患者1年生存率为83.33%(25/30),高于单纯放疗组患者的60.00%(18/30),差异有统计学意义(P﹤0.05)。结论放疗联合替吉奥治疗老年食管癌疗效优于单纯放疗,可提高生存率,但会增加部分不良反应。
Objective To compare the efficacy of radiotherapy combined with Tigio and radiotherapy alone for elderly patients with esophageal cancer. Method A total of 60 elderly patients with esophageal cancer were randomly divided into radiotherapy group and combination group with 30 cases in each group according to the random number table. Patients in radiotherapy group were treated with radiotherapy alone and those in combination group were treated with radiotherapy combined with Tigio. The clinical efficacy, incidence of adverse events and one-year survival rate of the two groups were compared. Result The overall efficacy in combination group was 86.67%(26/30), which is higher than60.00%(18/30) in radiotherapy group with significant difference(P<0.05). The incidence of myelosuppression, nausea and vomiting in combination group were significantly higher than those in radiotherapy group(P<0.05). There was no significant difference in the incidence of diarrhea, radiation esophagitis and radiation pneumonitis between the two groups(P>0.05). The one-year survival rate in combination group was 83.33%(25/30), which is higher than 60.00%(18/30) in radiotherapy group with significant difference(P<0.05). Conclusion Radiotherapy combined with Tigio capsule was superior to radiotherapy alone in the treatment for elderly patients with esophageal though increasing survival rate, but the combined regimen could increase the incidence of some adverse events.
Objective To compare the efficacy of radiotherapy combined with Tigio and radiotherapy alone for elderly patients with esophageal cancer. Method A total of 60 elderly patients with esophageal cancer were randomly divided into radiotherapy group and combination group with 30 cases in each group according to the random number table. Patients in radiotherapy group were treated with radiotherapy alone and those in combination group were treated with radiotherapy combined with Tigio. The clinical efficacy, incidence of adverse events and one-year survival rate of the two groups were compared. Result The overall efficacy in combination group was 86.67%(26/30), which is higher than60.00%(18/30) in radiotherapy group with significant difference(P<0.05). The incidence of myelosuppression, nausea and vomiting in combination group were significantly higher than those in radiotherapy group(P<0.05). There was no significant difference in the incidence of diarrhea, radiation esophagitis and radiation pneumonitis between the two groups(P>0.05). The one-year survival rate in combination group was 83.33%(25/30), which is higher than 60.00%(18/30) in radiotherapy group with significant difference(P<0.05). Conclusion Radiotherapy combined with Tigio capsule was superior to radiotherapy alone in the treatment for elderly patients with esophageal though increasing survival rate, but the combined regimen could increase the incidence of some adverse events.
引文
[1]贺宇彤,李道娟,梁迪,等. 2013年中国食管癌发病和死亡估计[J].中华肿瘤杂志, 2017, 39(4):315-320.
[2]陈兰兰,高立明,程少会,等.三维适形放疗同步替吉奥胶囊治疗局部晚期胃癌疗效观察[J].中国疗养医学, 2018,27(1):57-59.
[3]曹焱,潘慧丽,郑光浩,等.三维适形放疗联合替吉奥胶囊口服化疗治疗局部晚期胃癌疗效观察[J].现代生物医学进展, 2017, 17(16):3107-3110; 3132.
[4]穆克代斯·伊力亚斯,巴尔夏古丽·扎比胡拉,伊斯刊达尔·阿布力米提.替吉奥胶囊联合同步放疗治疗晚期胃癌的临床研究[J].中国临床药理学杂志, 2017, 33(22):2236-2238.
[5] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
[6] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group(RTOG)and the European Organization for Research and Treatment of Cancer(EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1341-1346.
[7] Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1):207-214.
[8]翟志刚,戴东方,朱海峰,等.适形调强放疗联合替吉奥和奈达铂治疗局部晚期食管癌的疗效观察[J].中国肿瘤临床与康复, 2018, 25(12):1420-1422.
[9]赵丹,王钖,王兰荣,等.周方案紫杉醇联合复方苦参注射液同步放化疗治疗局部晚期老年食管癌临床观察[J].辽宁中医杂志, 2017, 44(1):89-90.
[10]卢家希,陈晓品.紫杉醇联合卡铂化疗同期调强适形放疗对老年晚期宫颈癌患者疗效观察及对患者生活质量和免疫功能影响[J].重庆医科大学学报, 2018, 43(2):240-244.
[11] Jain S, Dhingra S. Pathology of esophageal cancer and Barrett's esophagus[J]. Ann Cardiothorac Surg, 2017, 6(2):99-109.
[12]许涛,景红霞,曹风军,等.调强放疗联合替吉奥同步治疗非手术老年食管癌的临床疗效[J].中国老年学杂志,2018, 38(5):1090-1093.
[13] Zheng X, Song X, Shao Y, et al. Prognostic role of tumorinfiltrating lymphocytes in esophagus cancer:a meta-analysis[J]. Cell Physiol Biochem, 2018, 45(2):720-732.
[2]陈兰兰,高立明,程少会,等.三维适形放疗同步替吉奥胶囊治疗局部晚期胃癌疗效观察[J].中国疗养医学, 2018,27(1):57-59.
[3]曹焱,潘慧丽,郑光浩,等.三维适形放疗联合替吉奥胶囊口服化疗治疗局部晚期胃癌疗效观察[J].现代生物医学进展, 2017, 17(16):3107-3110; 3132.
[4]穆克代斯·伊力亚斯,巴尔夏古丽·扎比胡拉,伊斯刊达尔·阿布力米提.替吉奥胶囊联合同步放疗治疗晚期胃癌的临床研究[J].中国临床药理学杂志, 2017, 33(22):2236-2238.
[5] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
[6] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group(RTOG)and the European Organization for Research and Treatment of Cancer(EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1341-1346.
[7] Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1):207-214.
[8]翟志刚,戴东方,朱海峰,等.适形调强放疗联合替吉奥和奈达铂治疗局部晚期食管癌的疗效观察[J].中国肿瘤临床与康复, 2018, 25(12):1420-1422.
[9]赵丹,王钖,王兰荣,等.周方案紫杉醇联合复方苦参注射液同步放化疗治疗局部晚期老年食管癌临床观察[J].辽宁中医杂志, 2017, 44(1):89-90.
[10]卢家希,陈晓品.紫杉醇联合卡铂化疗同期调强适形放疗对老年晚期宫颈癌患者疗效观察及对患者生活质量和免疫功能影响[J].重庆医科大学学报, 2018, 43(2):240-244.
[11] Jain S, Dhingra S. Pathology of esophageal cancer and Barrett's esophagus[J]. Ann Cardiothorac Surg, 2017, 6(2):99-109.
[12]许涛,景红霞,曹风军,等.调强放疗联合替吉奥同步治疗非手术老年食管癌的临床疗效[J].中国老年学杂志,2018, 38(5):1090-1093.
[13] Zheng X, Song X, Shao Y, et al. Prognostic role of tumorinfiltrating lymphocytes in esophagus cancer:a meta-analysis[J]. Cell Physiol Biochem, 2018, 45(2):720-732.